In summary, our studies demonstrated that COX-2 increased β1-integrin expression in NSCLC, and that EP1 activation increased E2F-1 expression, by binding to the FoxC2 promoter and promoting the expressions of FoxC2 and in turn, β1-integrin. Here, FOXC2 is linked to non-small cell lung carcinoma.